<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>ITANU Magazine: Science</title><link>https://itanu.org/magazine/desk/science/</link><description>Read the latest AI, hardware, software and science news. Clear reporting with original sources, plus space, cybersecurity and the business of technology.</description><language>en</language><lastBuildDate>Thu, 19 Nov 2026 05:31:20 GMT</lastBuildDate><atom:link href="https://itanu.org/magazine/desk/science/feed.xml" rel="self" type="application/rss+xml"/><item><title>FDA approves first drug for neurological symptoms in Type 3 Gaucher disease</title><link>https://itanu.org/magazine/fda-approves-first-drug-neurological-symptoms-gaucher-disease-oomhwxh6/</link><guid isPermaLink="true">https://itanu.org/magazine/fda-approves-first-drug-neurological-symptoms-gaucher-disease-oomhwxh6/</guid><pubDate>Thu, 19 Nov 2026 05:31:20 GMT</pubDate><dc:creator>ITANU Magazine newsroom</dc:creator><category>Science</category><description>Adults and children weighing at least 15 kg are eligible for Infilbray. In a 52-week trial, the tablets outperformed enzyme replacement therapy on a combined measure of muscle coordination and thinking.</description><content:encoded>&lt;h3&gt;Key points&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;Infilbray reaches the brain and reduces the buildup of fatty substances there.&lt;/li&gt;&lt;li&gt;The trial enrolled 43 patients aged 12 or older whose disease outside the nervous system had stabilized with enzyme replacement therapy.&lt;/li&gt;&lt;li&gt;The FDA cited reports of serious psychiatric effects, including suicidal thoughts and behavior.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;On 18 November the US Food and Drug Administration approved Infilbray, the first drug for neurological symptoms in Type 3 Gaucher disease. The approval covers venglustat tablets for adults and children weighing at least 15 kg.&lt;/p&gt;&lt;p&gt;In this rare inherited condition, an enzyme fails to break down certain fatty substances properly, allowing them to build up in the brain and elsewhere in the body. Patients can develop problems with balance, speech and memory that worsen over time. Infilbray can pass from the bloodstream into the brain and reduce the buildup there.&lt;/p&gt;&lt;p&gt;The phase 3 trial, called LEAP2MONO, enrolled 43 patients aged 12 or older whose disease outside the nervous system had stabilized with enzyme replacement therapy. Researchers randomly assigned participants to take a tablet daily or receive enzyme replacement by infusion every two weeks.&lt;/p&gt;&lt;p&gt;After 52 weeks, the tablet group did better on a measure that combined tests of muscle control and coordination with an assessment of thinking. Sanofi reported that the difference was statistically significant (p=0.0137).&lt;/p&gt;&lt;p&gt;The FDA listed digestive symptoms and changes in mood among the most commonly reported side effects. The agency also cited reports of serious psychiatric effects, including suicidal thoughts and behavior.&lt;/p&gt;&lt;h3&gt;Sources&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;a href=&quot;https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease&quot;&gt;FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease&lt;/a&gt;, U.S. Food and Drug Administration&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.pharmacytimes.com/view/fda-approves-venglustat-first-treatment-for-neurological-symptoms-of-gd3&quot;&gt;FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3&lt;/a&gt;, Pharmacy Times&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.news.sanofi.us/2026-11-18-Sanofis-Infilbray-approved-in-the-US-as-the-first-medicine-to-treat-neurological-manifestations-of-Type-3-Gaucher-disease&quot;&gt;Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease&lt;/a&gt;, Sanofi&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;ITANU’s newsroom system produced this article with AI and checked it against the sources listed above.&lt;/p&gt;</content:encoded></item><item><title>EMA announces mRNA update to seasonal flu vaccine guidance</title><link>https://itanu.org/magazine/ema-announces-mrna-update-flu-vaccine-guidance-xtgoisge/</link><guid isPermaLink="true">https://itanu.org/magazine/ema-announces-mrna-update-flu-vaccine-guidance-xtgoisge/</guid><pubDate>Tue, 17 Nov 2026 17:12:01 GMT</pubDate><dc:creator>ITANU Magazine newsroom</dc:creator><category>Science</category><description>The European Medicines Agency says its 2026/2027 recommendations now include mRNA influenza vaccines, alongside an update to its vaccine standardisation annex.</description><content:encoded>&lt;h3&gt;Key points&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;EMA says it added the mRNA vaccine recommendation on 17 November 2026.&lt;/li&gt;&lt;li&gt;The agency also reports an update to Annex I on vaccine standardisation reagents.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;The European Medicines Agency said it updated its 2026/2027 seasonal influenza vaccine composition recommendations on 17 November 2026 to include mRNA vaccines. The agency also reported changes to Annex I, which covers reagents used in vaccine standardisation.&lt;/p&gt;&lt;p&gt;EMA says the recommendations specify which influenza strains or sequences manufacturers should use in vaccines intended to prevent seasonal flu from autumn 2026. It directs readers to the latest document under its page’s ‘Related documents’ section for the additional strains and sequences.&lt;/p&gt;&lt;p&gt;According to the U.S. National Library of Medicine, mRNA stands for messenger RNA; in these vaccines, it provides instructions that cells use to produce a germ’s protein or a fragment of it. The resulting protein prompts an immune response, including antibody production, and cells subsequently break down the mRNA.&lt;/p&gt;&lt;p&gt;EMA’s update history lists earlier additions on 7 May 2026 concerning strains for egg-based and live-attenuated influenza vaccines. The agency says a further update on 26 May 2026 covered an A/H3N2 virus suitable for cell-based seasonal vaccines and a B-lineage virus suitable for live-attenuated seasonal vaccines.&lt;/p&gt;&lt;h3&gt;Sources&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;a href=&quot;https://www.ema.europa.eu/en/news/eu-recommendations-2026-2027-seasonal-flu-vaccine-composition&quot;&gt;EU recommendations for 2026/2027 seasonal flu vaccine composition&lt;/a&gt;, European Medicines Agency&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2026-2027-northern-hemisphere-influenza-season&quot;&gt;Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season&lt;/a&gt;, World Health Organization&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.medlineplus.gov/genetics/understanding/therapy/mrnavaccines/&quot;&gt;What are mRNA vaccines and how do they work?&lt;/a&gt;, U.S. National Library of Medicine&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;ITANU’s newsroom system produced this article with AI and checked it against the sources listed above.&lt;/p&gt;</content:encoded></item></channel></rss>
